k8凯发(中国)

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON LM-350 "CDH17 ADC" APPROVED BY THE NMPA

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2025

VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER WAS PRESENTED AT ESMO 2025

VOLUNTARY ANNOUNCEMENT - INCLUSION OF TQ-B3234 “SELECTIVE MEK1/2 INHIBITOR” IN THE BREAKTHROUGH THERAPY DESIGNATION PROCESS

VOLUNTARY ANNOUNCEMENT - TQB2102 "HER2 BISPECIFIC ADC" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2025

NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS

NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED HOLDERS